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Abstract
The hippocampus has been the target of stem cell transplantations in preclinical
studies focused on Alzheimer’s disease, with results showing improvements in
histological and behavioral outcomes. The corpus callosum is another structure
that is affected early in Alzheimer’s disease. Therefore, we hypothesize that this
structure is a novel target for human neural stem cell transplantation in trans-
genic Alzheimer’s disease mouse models. This study demonstrates the feasibility
of targeting the corpus callosum and identifies an effective immunosuppression
regimen for transplanted neural stem cell survival. These results support fur-
ther preclinical development of the corpus callosum as a therapeutic target in
Alzheimer’s disease.
Introduction
Cellular therapies represent a potential disease-modify-
ing treatment for Alzheimer’s disease (AD), with multi-
faceted therapeutic benefits including tissue replacement,
secretion of neuroprotective trophic factors, and/or
modulation of inflammation.1–6 As such, transplantation
of stem cells from various sources into the hippocam-
pus improves cognitive impairment in murine AD
models.1,7,8 With the success of hippocampal targeting,
interest has grown in identifying other intracranial tar-
gets suitable for stem cell transplantation. One of the
proposed targets is the corpus callosum (CC), a large
white matter tract that includes the neural pathway
starting at the nucleus basalis of Meynert, and connects
the majority of frontal, parietal, and occipital cortical
areas to corresponding regions in the contralateral
hemisphere. CC size changes and atrophy occur in AD
patients and correlate with progression of dementia
severity.9–11 This, coupled with the fact that stem cells
migrate through large white matter tracts,12–14 makes
the CC a potentially effective target. We therefore
hypothesize that the CC is an ideal treatment target for
cellular therapies for AD. Here, we assessed optimal
immunosuppression and the feasibility of CC targeting
with a modified human neural stem cell (NSC) line,
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which we previously characterized and targeted to the
fimbria fornix of AD mice.15
Materials and Methods
Surgical transplantation of NSCs to the CC
All procedures were approved by the University of Michi-
gan (U-M) Institutional Animal Care and Use Commit-
tee. Male Tg-AD B6C3-Tg(APPswe/PSEN1DE9)85Dbo/J
(APP/PS1) mice were obtained from the Jackson Labora-
tory (Bar Harbor, ME). Research grade human NSCs,
NSI-HK532-IGF-I, a modified line we previously charac-
terized,15 were provided by Neuralstem, Inc. (German-
town, MD). NSCs were administered to 12-week-old mice
by three injections into the CC bilaterally at three sites
(total six injections), represented by the following atlas
coordinates from the bregma (posterior, lateral, ventral):
0.82/()0.6/1.9, 1.82/()0.6/1.5, 2.3/()0.6/1.5 mm,
respectively. Each 1 lL injection was administered over
60 sec, with a 60-sec delay prior to needle withdrawal, at
a cell concentration of 30,000 cells/lL, delivering a total
of 180,000 cells per animal.
Immunosuppression
Tacrolimus (FK-506, Prograf, Astellas Pharmas US Inc.,
Northbrook, IL) was administered subcutaneously to all
animals at 3 mg/kg starting 2 days prior to surgery and
daily until postoperative day #6. On the day of the
procedure and daily for 6 days later (seven doses total),
30 mg/kg of mycophenolate mofetil (CellCept; Genentech
USA Inc., South San Francisco, CA) was administered
subcutaneously in conjunction with the tacrolimus. On
postoperative day #7, CellCept was discontinued and ani-
mals were randomly assigned to three groups (n = 5 per
group) to assess three tacrolimus doses: 0.3 mg/kg,
1.5 mg/kg, and 3 mg/kg.
Immunohistochemical analyses
The following primary antibodies were applied overnight
at 4°C (Table S1) and detected with appropriate Alexa
Fluor-conjugated secondary antibodies (Thermo Fisher
Scientific, Hampton, NH): human-specific anti-human
nuclei (HuNu; Millipore, Billerica, MA), glial fibrillary
acidic protein (GFAP; Dako, Carpinteria, CA), and oligo-
dendrocyte-specific protein (OSP; Abcam, Cambridge,
UK). DAPI and Nissl stains (Thermo Fisher Scientific)
were used to visualize nuclei and neurons, respectively.
Fluorescent images were captured by an investigator
blinded to treatment groups using Leica SP2 confocal
(Leica Microsystems, Buffalo Grove, IL) and Nikon
Microphot-FXA (Nikon Instruments, Chiyoda, Japan)
microscopes. Engrafted HuNu-positive NSCs were
counted in 10–15 coronal sections per animal (n = 2 per
group), for average counts over ~140 lm within the
injection coordinates. Statistical significance was deter-
mined by one-way analysis of variance followed by
Tukey’s multiple comparison test using GraphPad Prism
(GraphPad Software Inc., La Jolla, CA) Data S1.
Results
Survival, migration, and differentiation of
NSCs targeted to the CC
There were no animal deaths or morbidity postopera-
tively, and all 15 mice were healthy until study end at
4 weeks posttransplantation. The CC was successfully
targeted, as injection tracts were located in all animals
at the correct anatomical location (data not shown)
and further demonstrated by the presence of HuNu-
positive engrafted cells within the CC of animals that
received adequate immunosuppression of 3 mg/kg
tacrolimus (Fig. 1). In this group, extensive graft sur-
vival and migration was observed, with HuNu-positive
NSCs present throughout and adjacent to the CC.
NSCs were located throughout the entire ~1.7 mm
injection area, on average migrating 1 mm beyond the
injection site (data not shown). The largest distribution
in one animal spanned a total of 2.2 mm, indicating a
migration distance of ~0.5 mm (Fig. 1A–D). This shows
that the CC can be successfully, accurately, and safely
targeted in 12-week-old Tg-AD mice, and that trans-
planted NSCs survive and migrate in this brain struc-
ture 4 weeks postoperatively when immunosuppression
levels are adequate. We also performed phenotypic
analyses of transplanted NSCs in the 3 mg/kg group
(Fig. 2). Evidence of neuronal and astrocytic differentia-
tion was noted, defined by Nissl and GFAP co-localiza-
tion with HuNu, respectively. We did not observe
oligodendrocyte differentiation, with no evident HuNu
and OSP co-localization.
Minimum dose of immunosuppression for
transplanted NSC survival in the CC
Minimizing immunosuppression dosages is desirable in
order to mitigate drug-related side-effects that may affect
health and subsequent behavior. We assessed the effect of
three levels of tacrolimus immunosuppression on NSC
survival. In animals treated with 0.3 mg/kg, no HuNu-
positive cells were detectable 4 weeks postoperatively
(Fig. 3A). With 1.5 mg/kg, NSCs were identified in four
of five mice. HuNu-positive NSCs were present in all five
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Figure 1. Transplanted NSCs survive and migrate in the CC of AD mice. Accurate targeting of NSCs to the CC of the Tg-AD mouse brain
(3.0 mg/kg tacrolimus). Representative confocal imaging of transplanted NSC survival and migration along the white matter tract structure (A–D).
High magnification of the grafted area showing clear migration of NSCs beyond the injection points (E). NSCs labeled with HuNu (red; also
shown in black and white); neurons labeled with Nissl (green). CC, corpus callosum; Arrows indicate targeted sites of injection. A–D: scale bar
1.5 mm; E: scale bar 300 lm.
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mice that received 3 mg/kg tacrolimus (Fig. 3B–C). Qual-
itative cell counts show that 3.0 mg/kg tacrolimus signifi-
cantly increased NSC survival compared to the other
doses tested (Fig. 3D). These data indicate that the mini-
mum dose of tacrolimus required to support survival of
this human NSC line after transplantation to the CC is
3 mg/kg daily.
Discussion
With hippocampal-targeted stem cell therapies improv-
ing AD-associated cognitive deficits in preclinical mod-
els, comes an opportunity to identify novel targets that
could be equally or increasingly efficacious in disease
treatment. The CC is a prime target, given that it is
the largest white matter tract affected early in AD.11
Moreover, it connects numerous areas of the brain,
including the nucleus basalis of Meynert, a cholinergic
structure affected in AD.9 Targeting the CC can also
theoretically facilitate increased migration of trans-
planted cells, providing additional trophic support and
a source of neuroglial tissue to larger areas, including
the orbital and prefrontal regions, thereby having a
greater impact on AD pathology. This study demon-
strates the feasibility of targeting the CC in a relevant
preclinical model of AD and identifies an effective
tacrolimus-based immunosuppression regimen for sur-
vival and engraftment of a novel NSC line, which we
are currently exploring as a potential candidate for
therapeutic development.15
As shown in Figure 1, we safely and accurately targeted
the CC, with no complications postoperatively through-
out the study period. Interestingly, transplanted NSCs
migrated along the tracts of the CC, traversing distances
up to 0.5 mm outside of injection points. This is in line
with many reports of stem cell migration via white matter
tracts.12–14 Given that stem cell efficacy is improved when
coupled with trophic factor delivery,2,16–18 facilitating
increased NSC migration could provide enhanced and
widespread neurotrophic support to local brain areas.
Moreover, targeting the CC provides the largest migratory
area for transplanted stem cells, likely more than any
other intracranial target, enabling further enrichment
throughout the diseased brain environment. We also
assessed the differentiation profile of transplanted NSCs.







Figure 2. Differentiation profile of transplanted NSCs. Representative phenotypic analyses of transplanted NSCs (3 mg/kg tacrolimus).
Differentiation into neuronal and astrocytic lineages indicated by GFAP and Nissl co-localization with HuNu; examples are marked with arrows
(A–B). No oligodendrocyte differentiation was observed (C). NSCs labeled with HuNu (green); GFAP, Nissl, and OSP indicate differentiation (red).
Scale bar 50 lm.
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neuronal and glial lineages in vitro and in vivo in nude
rats (data not shown). Although we observed similar
results, with low levels of neuronal and astrocytic differ-
entiation, there was no evidence of oligodendrocyte dif-
ferentiation in this study. Of course, diverse
differentiation profiles are expected depending upon
transplantation location, and with this short 4-week study
duration, it is possible that many transplanted NSCs
remained in an undifferentiated or progenitor state.1,19






































Figure 3. Immunosuppression requirement for CC-targeted NSC survival in AD mice. Representative confocal imaging of NSC 4 weeks after CC
targeting in Tg-AD mice immunosuppressed with tacrolimus at 0.3 mg/kg (A) and 3.0 mg/kg (B). Immunosuppression with 0.3 mg/kg shows no
evidence of surviving NSCs in the targeted area (A). HuNu-positive NSCs are visible in the CC at the 3.0 mg/kg dose, with extensive NSC survival
and migration along the white matter tract structure (B–C). NSCs are labeled with HuNu (red); nuclei are labeled with DAPI (blue); CC, corpus
callosum; GS, grayscale. (A–C) scale bar 200 lm; D: scale bar 100 lm. Cell counts expressed as average numbers of HuNu-positive cells over a
distance of 140 lm within the injection coordinates (0.8 to 1.6 mm from bregma) show significantly increased NSCs with 3.0 mg/kg
tacrolimus versus other doses tested (D). (*P < 0.05).
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terminal differentiation markers will be required in future
long-term efficacy studies to disclose possible therapeutic
mechanisms of cell transplantation.
With regard to immunosuppression, previous studies
in our laboratory utilized 3 mg/kg tacrolimus, which is
largely based on other rodent species.20 As further dose
reduction could potentially mitigate the toxic side-
effects of prolonged immunosuppression, we assessed
three dosing regimens. At 1.5 mg/kg tacrolimus, trans-
planted NSCs were observed in only four of the five
animals and HuNu-positive cell counts were signifi-
cantly reduced at this dose compared to 3 mg/kg.
Given the reliability of cell targeting and preserved cell
viability after the injection procedure, the 1.5 mg/kg
dose is likely close to the threshold where the immune
system could still reject the transplanted human cells,
even in the presence of tacrolimus. Based on these
data, we report that 3 mg/kg tacrolimus administered
subcutaneously is the minimum dosage necessary for
reliable human NSC engraftment in this Tg-AD mouse
model. However, it is possible that only a minority of
Tg-AD mice will reject cells at the 1.5 mg/kg dose of
tacrolimus and that we observed an enrichment of this
phenomenon due to our small sample size. Repeating
both intermediate and high doses of tacrolimus in
additional animals and for a longer duration is neces-
sary and should be addressed in future interventional
studies targeting the CC.
In summary, the CC is affected early in the course of
AD, and this pilot study assessed the feasibility of target-
ing this white matter structure, as this has not yet been
determined in preclinical Tg-AD mouse models. Here, for
the first time, we demonstrate that the APP/PS1 mouse
CC can be accurately and safely targeted for stem cell
transplantation. We also define an effective immunosup-
pression regimen and report that subcutaneous injection
of 3 mg/kg tacrolimus is the minimum dose necessary for
survival of this human NSC line. Together, these data
demonstrate the feasibility of CC targeting and support
further evaluation of CC-targeted stem cell therapies in
AD.
Acknowledgments
The authors thank Holly Wagner and Stacey A. Sakowski,
Ph.D. (University of Michigan) for administrative and edi-
torial support. Funding was provided by the A. Alfred
Taubman Medical Research Institute, the Program for
Neurology Research & Discovery, and the Robert E. Ned-
erlander Sr. Program for Alzheimer’s Research. K.S.C. and
O.N.K. were supported by the University of Michigan
Clinician Scientist Training Programs (Grants NINDS
R25NS089450 and NIH T32NS07222).
Author Contributions
L.M.M. and O.N.K. designed the study, and collected,
analyzed, and interpreted data, and wrote the manuscript.
K.S.C., J.M.H., and C.B. collected, analyzed, and inter-
preted data and edited the manuscript. E.S.B., S.F., and
B.N.K. collected and analyzed data and edited the manu-
script. K.J. designed the study and provided study materi-
als. E.L.F. designed and directed the study, contributed to
discussion, edited and approved the manuscript, and pro-
vided financial support.
Conflict of Interest
K.J. is the chief scientific officer of Neuralstem, Inc., but
was not involved in data acquisition or analysis. E.L.F. is
an unpaid consultant to Neuralstem, Inc. All other
authors have no conflicts of interest to disclose.
References
1. Ager RR, Davis JL, Agazaryan A, et al. Human neural
stem cells improve cognition and promote synaptic
growth in two complementary transgenic models of
Alzheimer’s disease and neuronal loss. Hippocampus.
2015;25:813–826.
2. Blurton-Jones M, Kitazawa M, Martinez-Coria H, et al.
Neural stem cells improve cognition via BDNF in a
transgenic model of Alzheimer disease. Proc Natl Acad Sci
USA 2009;106:13594–13599.
3. Gu G, Zhang W, Li M, et al. Transplantation of NSC-
derived cholinergic neuron-like cells improves cognitive
function in APP/PS1 transgenic mice. Neuroscience
2015;291:81–92.
4. Hampton DW, Webber DJ, Bilican B, et al. Cell-mediated
neuroprotection in a mouse model of human tauopathy. J
Neurosci 2010;30:9973–9983.
5. Lee IS, Jung K, Kim IS, et al. Human neural stem cells
alleviate Alzheimer-like pathology in a mouse model. Mol
Neurodegener 2015;10:38.
6. Zhang W, Wang PJ, Sha HY, et al. Neural stem cell
transplants improve cognitive function without altering
amyloid pathology in an APP/PS1 double transgenic model
of Alzheimer’s Disease. Mol Neurobiol 2014;50:423–437.
7. Lee HJ, Lee JK, Lee H, et al. Human umbilical cord blood-
derived mesenchymal stem cells improve neuropathology
and cognitive impairment in an Alzheimer’s disease mouse
model through modulation of neuroinflammation.
Neurobiol Aging 2012;33:588–602.
8. Lee JK, Jin HK, Bae JS. Bone marrow-derived
mesenchymal stem cells reduce brain amyloid-beta
deposition and accelerate the activation of microglia in an
acutely induced Alzheimer’s disease mouse model.
Neurosci Lett 2009;450:136–141.
754 ª 2017 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Stem Cell Transplantation into the Corpus Callosum L. M. McGinley et al.
9. Hong JH, Jang SH. Neural pathway from nucleus basalis
of Meynert passing through the cingulum in the human
brain. Brain Res 2010;1346:190–194.
10. Teipel SJ, Bayer W, Alexander GE, et al. Progression of
corpus callosum atrophy in Alzheimer disease. Arch
Neurol 2002;59:243–248.
11. Di Paola M, Spalletta G, Caltagirone C. In vivo structural
neuroanatomy of corpus callosum in Alzheimer’s disease
and mild cognitive impairment using different MRI
techniques: a review. J. Alzheimer’s Dis. 2010;20:67–95.
12. Chen CC, Hsu YH, Jayaseema DM, et al. White matter
tracts for the trafficking of neural progenitor cells
characterized by cellular MRI and immunohistology: the
role of CXCL12/CXCR4 signaling. Brain Struct Funct
2015;220:2073–2085.
13. Suzuki SO, Goldman JE. Multiple cell populations in the
early postnatal subventricular zone take distinct migratory
pathways: a dynamic study of glial and neuronal
progenitor migration. J Neurosci 2003;23:4240–4250.
14. Yang J, Liu J, Niu G, et al. In vivo MRI of endogenous
stem/progenitor cell migration from subventricular zone in
normal and injured developing brains. NeuroImage
2009;48:319–328.
15. McGinley LM, Sims E, Lunn JS, et al. Human cortical
neural stem cells expressing insulin-like growth factor-I: a
novel cellular therapy for Alzheimer’s Disease. Stem Cells
Transl Med 2016;5:379–391.
16. Blurton-Jones M, Spencer B, Michael S, et al. Neural stem
cells genetically-modified to express neprilysin reduce
pathology in Alzheimer transgenic models. Stem Cell Res
Ther 2014;5:46.
17. Garcia KO, Ornellas FL, Martin PK, et al. Therapeutic
effects of the transplantation of VEGF overexpressing bone
marrow mesenchymal stem cells in the hippocampus of
murine model of Alzheimer’s disease. Front Aging
Neurosci 2014;6:30.
18. Martinez-Serrano A, Bjorklund A. Protection of the
neostriatum against excitotoxic damage by neurotrophin-
producing, genetically modified neural stem cells. J
Neurosci 1996;16:4604–4616.
19. Naimi S, Jeny R, Hantraye P, et al. Ontogeny of human
striatal DARPP-32 neurons in fetuses and following
xenografting to the adult rat brain. Exp Neurol
1996;137:15–25.
20. Hefferan MP, Johe K, Hazel T, et al. Optimization of
immunosuppressive therapy for spinal grafting of human
spinal stem cells in a rat model of ALS. Cell Transplant
2011;20:1153–1161.
Supporting Information
Additional Supporting Information may be found online
in the supporting information tab for this article:
Data S1. Materials and Methods
Table S1. List of primary antibodies and stains used for
immunohistochemical analyses including manufacturer, cata-
log number, dilution factor, and applied secondary antibody.
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